- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Every child and adolescent living with HIV should have access to antiretroviral therapy (ART). The AIDS Free component of the framework has the specific goal of ensuring 95% of all children and adolescents living with HIV have access to lifelong ART by the end of 2018. These efforts will need to be sustained until 2020, when it is estimated that treating 95% of all children and adolescents living with HIV will require providing ART to 1.4 million children (aged 0-14). and 1 million adolescents (aged 15-19).
The aim of the report is to document participation efforts and outcomes across countries, and highlight differences and constraints identified to date. In this first GLASS report data vary considerably in terms of completeness, so no attempt was made to compare AMR status at a regional or global level. However, as GLASS and country participation evolves, the data reported will help understand surveillance capacities and mechanisms of reporting across countries in all regions, and will inform further GLASS development.
AVAC's 2018 annual state of the field report, No Prevention, No End! looks at today's prevention crisis and offers context, analysis and strategy to turn that crisis around.
Keywords: HIV, PrEP, treatment, vaccine, prevention
Update on antiretroviral regimens for treating and preventing HIV infection: Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment.
Update on early infant diagnosis of HIV: In 2016, WHO recommended that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result.
Keywords: HIV, ART, diagnosis, treatment
This report summarizes the progress in implementing the Global Action Plan achieved during the first year (2017 to 2018) and the remaining challenges, with specific focus on 45 countries accounting for more than 85% of the total burden of HIV infection.
Keywords: HIVDR, prevention, response, surveillance, monitoring
Twenty years of evidence demonstrates that HIV treatment is highly effective in reducing the transmission of HIV. People living with HIV on antiretroviral therapy who have an undetectable level of HIV in their blood have a negligible risk of transmitting HIV sexually.
This report presents 2015 data on the consumption of systemic antibiotics from 65 countries and areas, contributing to our understanding of how antibiotics are used in these countries. In addition, the report documents early efforts of the World Health Organization (WHO) and participating countries to monitor antimicrobial consumption, describes the WHO global methodology for data collection, and highlights the challenges and future steps in monitoring antimicrobial consumption.
Strong global commitment to end AIDS has driven huge progress. In 2017, around 75% of people living with HIV globally knew their HIV status and 59% of all people living with HIV were accessing treatment.
However, new HIV infections are not declining fast enough and too many people are still dying from AIDS-related illnesses despite the availability of high-quality and effective treatment. And with 36.9 million men, women and children living with HIV around the world, there are more people than ever before living with HIV. A quarter don’t even know that they have the virus.
There is a belief that innovation of new antibiotics will out-pace the development and spread of resistant bacteria. However, without rapidly addressing the way antibiotics are currently over- and mis-used, there is no chance of winning this race. Novel antibiotics will continue to play an important role, but they will not be enough. Antibiotics must be seen as a non-renewable resource. And just like in climate change, if this natural resource is exhausted, there will be nothing left for future generations. Managing antibiotic resistance relies on limiting use of antibiotics, discovery of new antibiotics or alternative ways to treat infectious diseases, but also on preventing infections and limiting spread of resistance. There are no quick fixes – antibiotic resistance is a systems failure and thus all sectors need to contribute to a change and jointly securing that antibiotics remain effective.
This report focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment.
This strategic framework provides a road map to scale-up PPTCT services in the most efficient manner, where value for money is achieved with the promise that no infected mother will be missed and no child will be born with HIV, where every HIV exposed infant will receive the much needed HIV test at 6 weeks of age, and linked to treatment where required.